Bio Break: Clinical Trials for Medical Devices vs. Pharmaceuticals

Resources

Bio Break: Clinical Trials for Medical Devices vs. Pharmaceuticals

Topic: Bio Break

In this episode of Bio Break, Joris van der Heijden and Nick Allan break down the key differences and similarities between clinical trials for medical devices and pharmaceutical products. As the conversation unfolds, they provide valuable insights into the distinct processes and challenges associated with these two types of trials, including the complexities of combination devices that bridge both worlds.

Nick begins by explaining the unique goals of clinical trials for medical devices. These trials focus on proving safety, efficacy, and the performance claims of the device in real-world settings. For example, diagnostic devices must demonstrate their ability to detect targets reliably and accurately, whether in a clinical laboratory or at the point of care.

In contrast, Nick outlines the four distinct phases of pharmaceutical clinical trials:

  • Phase 1: Conducted with healthy volunteers to evaluate safety and dosage, often involving a small group of participants (around 50 people).
  • Phase 2: Tests the drug’s efficacy in the target patient population, expanding the study to hundreds of participants.
  • Phase 3: Compares the drug against existing treatments or the standard of care in a much larger population, often with thousands of participants, to prove differentiation and effectiveness.
  • Phase 4: Post-market surveillance monitors long-term safety, side effects, and real-world performance after regulatory approval.

Nick highlights how medical device trials share parallels with pharmaceutical trials but often focus on different priorities, such as functional testing, usability, and regulatory claims. The discussion becomes especially intriguing when considering combination products, which integrate medical devices with pharmaceutical components, requiring alignment across both regulatory pathways and clinical trial objectives.

This episode is essential viewing for anyone working in medical device development, pharmaceuticals, or combination products. Gain a clear understanding of the clinical trial landscape and how these processes ensure safety, efficacy, and market readiness for innovative healthcare solutions.

Clinical Trials for Medical Devices vs. Pharmaceuticals

YouTube video thumbnail
A fluorescent protein assay sample glows under UV light as part of medical device cleaning validation testing.

Fluorescent Protein Assay Testing in Medical Devices

Nick Allan and Nigel Syrotuck explain how a fluorescent protein assay helps engineers measure contamination and cleaning performance in medical devices.

Engineer assembling electronic components during medical device design transfer process.

Bridging the Design-to-Manufacturing Gap in Medical Devices

Your team is ready for design validation. The prototype performs well, test plans are in motion, and everything points to a smooth handoff to manufacturing. Then your partner calls with bad news: they can’t build the device as designed.

Contract Manufacturer Rejection - Engineering team reviews early-stage medical device design and manufacturability during a design transfer meeting at StarFish Medical.

When the CM Says No: What to Do When Your Contract Manufacturer Rejects Your Early-Stage Build

You’ve cleared the toughest engineering hurdles and proven your design works. Then, just as you prepare to scale, your contract manufacturer turns you down.

Black cubes with white arrows changing direction, symbolizing strategic pivots and disciplined commercialization in MedTech exit optimization.

Exit Optimization: Building Strategic Optionality

In Medtech, a successful exit isn’t just about having an innovative device, it’s about building a business that potential buyers and investors can clearly see a future in.